Medisi America
  • Home
  • We Are
  • Services
  • News
  • Contact Us
  • en EN
    • en EN
    • fr FR
    • de DE
    • it IT
    • pt PT
    • ru RU
    • es ES

Finding a non-invasive way to predict effectiveness of cancer therapy.

By Medisi America on 30 diciembre, 2019

«Researchers have taken a critical step toward developing a non-invasive nuclear medicine technique that can predict the effectiveness of therapy for cancerous tumors, allowing for personalized, precision treatment.»

Read more.

 

Posted in News.
Share
←  NewerResMed ventilators recall is Class I
Older  →Medical Devices; Exemptions From Premarket Notification for Class I and Class II Devices

Entradas recientes

  • COFEPRIS Evolves
  • COFEPRIS Challenges 2020
  • ResMed ventilators recall is Class I
  • Finding a non-invasive way to predict effectiveness of cancer therapy.

NEWS

  • Conferences
  • News
  • Science
  • Technology

Deja una respuesta Cancelar la respuesta

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

Related Posts

  • 18 junio, 2019

    Using EEG data to diagnose Parkinson’s disease

    Researchers behind a new study believe that an EEG may be a more effective alternative. If you want to read more about this news click here  

  • 30 diciembre, 2019

    Researchers produce first laser ultrasound images of humans.

    «Engineers have come up with an alternative to conventional ultrasound that doesn’t require contact with the body to see inside a patient. The new laser ultrasound technique leverages an eye- and skin-safe laser system to remotely image the inside of a person.»   Read more

  • 19 febrero, 2020

    ResMed ventilators recall is Class I

    FDA today designated a ResMed (NYSE:RMD) recall of certain Stellar non-invasive and invasive ventilators as Class I — the agency’s most serious level. The sound alarm on the ventilators may not work if the device has a failed electronic part, is stored without AC power for more than 36 hours, or powers on automatically when connected …

  • 10 octubre, 2019

    Study: Abbott, Edwards may have mislabeled hundreds of patient deaths

    Abbott (NYSE:ABT) and Edwards Lifesciences (NYSE:EW) may have mislabeled patient deaths as injuries or device malfunctions in hundreds of FDA adverse event reports involving their transcatheter aortic or mitral valve replacement devices, according to a new study. The study by JAMA Internal Medicine editor Dr. Rita Redberg, former FDA unique device identification (UDI) external program manager Madris Tomes and others examined a total …

  • © 2026 MEDISI America - All rights reserved
  • Home
  • We Are
  • Services
  • News
  • Contact Us
  • en EN
    • en EN
    • fr FR
    • de DE
    • it IT
    • pt PT
    • ru RU
    • es ES